United States set
Menu Shopping cart $0 Search
Manufactured by BioVendor

Visfatin (NAMPT) Mouse/Rat ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, HRP-labelled antibody
  • Other names:NAMPT, Pre-B cell colony-enhancing factor, PBEF, Nicotinamide phosphoribosyltransferase, NAmPRTase, EC=, Pre-B-cell colony-enhancing factor 1, PBEF1, NAMPT
  • Species:Mouse, Rat
Cat. No. Size Price

RAG009R 96 wells (1 kit) $694
PubMed Product Details
Technical Data


Sandwich ELISA, HRP-labelled antibody




At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.5–32 ng/ml

Limit of Detection

50 pg/ml


Research topic

Cytokines and chemokines and related molecules, Energy metabolism and body weight regulation, Animal studies


Excess adiposity is the most important risk in the development of insulin resistance and type 2 diabetes mellitus (T2DM). Adipose tissue produces several proteins (adipocytokines) such as leptin, adiponectin, resistin, tumor necrosis factor-α, and IL-6, that modulate insulin sensitivity and appear to play an important role in the pathogenesis of insulin resistance, diabetes, dyslipidemia, inflammation, and atherosclerosis. However, the mechanisms by which fat tissue induces insulin resistance and the role of adipocytokines in the pathogenesis of T2DM have not been well established. Visfatin, also known as pre-B cell colony-enhancing factor (PBEF), is a cytokine that is highly expressed in visceral fat and was originally isolated as a secreted factor that synergizes with IL-7 and stem cell factors to promote the growth of B cell precursors. Visfatin homologs have been identified in carp, invertebrate mollusks , and bacteria, as well as in vertebrates, including humans and the mouse. It has been postulated to play a role in innate immunity. Visfatin exerts insulin-mimetic effects that are dose-dependent and quantitatively similar to those of insulin in stimulating muscle and adipocyte glucose transport, and in inhibiting hepatocyte glucose production. Intravenous injection of recombinant visfatin in mice decreased plasma glucose in a dose-dependent fashion. In keeping with its insulin-mimetic effects, visfatin was as effective as insulin in reducing hyperglycemia in insulin-deficient diabetic mice. Visfatin was also found to be bound to and activate insulin receptor, causing receptor phosphorylation and the activation of downstream signaling molecules. However, visfatin and insulin did not compete for binding to the insulin receptor, indicating that the two proteins were recognized by different regions of the receptor. Thus, visfatin might play a role in glucose homeostasis and dysregulation in biosynthesis or signal transduction, and might contribute to the pathogenesis of diabetes.

Product References (2)


  • Hülser ML, Luo Y, Frommer K, Hasseli R, Köhler K, Diller M, Van Nie L, Rummel C, Roderfeld M, Roeb E, Schett G, Bozec A, Müller-Ladner U, Neumann E. Systemic versus local adipokine expression differs in a combined obesity and osteoarthritis mouse model. Sci Rep. 2021 Aug 20;11(1):17001. doi: 10.1038/s41598-021-96545-8. PubMed PMID: 34417537. PubMed CentralPMCID: PMC8379250. See more on PubMed
  • Liu L, Wang P, Liang C, He D, Yu Y, Liu X. Distinct effects of Nampt inhibition on mild and severe models of lipopolysaccharide-induced myocardial impairment. Int Immunopharmacol. 2013 Oct;17(2):342-9. doi: 10.1016/j.intimp.2013.06.017. Epub 2013 Jul 2. PubMed PMID: 23831038. See more on PubMed
Summary References (11)

References to Visfatin

  • Arner P. Visfatin--a true or false trail to type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006 Jan;91 (1):28-30
  • Beltowski J. Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity?. Med Sci Monit. 2006 Jun;12 (6):RA112-9
  • Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, Stumvoll M, Bluher M. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes. 2005 Oct;54 (10):2911-6
  • Bottcher Y, Teupser D, Enigk B, Berndt J, Kloting N, Schon MR, Thiery J, Bluher M, Stumvoll M, Kovacs P. Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans. J Clin Endocrinol Metab. 2006 Jul;91 (7):2725-31
  • Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006 Jan;91 (1):295-9
  • Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R, Bouloumie A. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia. 2006 Apr;49 (4):744-7
  • Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005 Jan 21;307 (5708):426-30
  • Haider DG, Mittermayer F, Schaller G, Artwohl M, Baumgartner-Parzer SM, Prager G, Roden M, Wolzt M. Free fatty acids normalize a rosiglitazone-induced visfatin release. Am J Physiol Endocrinol Metab. 2006 Nov;291 (5):E885-90
  • Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab. 2006 Apr;91 (4):1578-81
  • Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, Milan G, Rossato M, Federspil G, Vettor R. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab. 2006 Aug;91 (8):3165-70
  • Pfutzner A, Forst T. Comment on: Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M (2006) the release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 49:1909-1914. Diabetologia. 2006 Nov;49 (11):2795; author reply 2796
Related Products Docs